Veldoreotide
As of the edition of 20 October 2026, Veldoreotide is a protein: went quiet in 2016; acts on SSTR2, SSTR4 and SSTR5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2016
- Kind
- Protein
- Registered trials
- 5, 0 stopped early
- Disease areas
- Bones, joints and muscles; Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product3 company-target rows are on route A because of Veldoreotide.
See the 3 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Aspireo Pharmaceuticals | Lead sponsor of trials | 2012 to now |